130 related articles for article (PubMed ID: 37743566)
1. Evaluating hybrid controls methodology in early-phase oncology trials: A simulation study based on the MORPHEUS-UC trial.
Wang G; Poulin-Costello M; Pang H; Zhu J; Helms HJ; Reyes-Rivera I; Platt RW; Pang M; Koukounari A
Pharm Stat; 2024; 23(1):31-45. PubMed ID: 37743566
[TBL] [Abstract][Full Text] [Related]
2. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.
Li C; Ferro A; Mhatre SK; Lu D; Lawrance M; Li X; Li S; Allen S; Desai J; Fakih M; Cecchini M; Pedersen KS; Kim TY; Reyes-Rivera I; Segal NH; Lenain C
Commun Med (Lond); 2022; 2():90. PubMed ID: 35856081
[TBL] [Abstract][Full Text] [Related]
3. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
Harun N; Liu C; Kim MO
Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
7. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
8. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
Su L; Chen X; Zhang J; Yan F
JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
[TBL] [Abstract][Full Text] [Related]
9. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
Jin H; Kim MO; Scheffler A; Jiang F
Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
[TBL] [Abstract][Full Text] [Related]
10. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
[TBL] [Abstract][Full Text] [Related]
11. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
12. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
13. Bayesian basket trial design with false-discovery rate control.
Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
[TBL] [Abstract][Full Text] [Related]
14. Bayesian sample size determination in basket trials borrowing information between subsets.
Zheng H; Grayling MJ; Mozgunov P; Jaki T; Wason JMS
Biostatistics; 2023 Oct; 24(4):1000-1016. PubMed ID: 35993875
[TBL] [Abstract][Full Text] [Related]
15. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
Fu C; Pang H; Zhou S; Zhu J
Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
[TBL] [Abstract][Full Text] [Related]
16. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
Chen X; Zhang J; Jiang Q; Yan F
J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
[TBL] [Abstract][Full Text] [Related]
17. An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma.
Normington J; Zhu J; Mattiello F; Sarkar S; Carlin B
Contemp Clin Trials; 2020 Feb; 89():105890. PubMed ID: 31740427
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
[TBL] [Abstract][Full Text] [Related]
19. Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.
Zheng H; Wason JMS
Biostatistics; 2022 Jan; 23(1):120-135. PubMed ID: 32380518
[TBL] [Abstract][Full Text] [Related]
20. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
